What Does Beta Bionics, Inc.'s 37% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline

Suit alleges Beta Bionics, Inc. failed to disclose key facts to investors from July 30, 2025 through February 24, 2026; lead plaintiff deadline is November 3, 2026

BENSALEM TOWNSHIP, Pa., Oct. 27, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith today reported that a securities class action lawsuit is pending against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors who acquired its securities from July 30, 2025 through February 24, 2026. The Beta Bionics, Inc. case, Holtzman v. Beta Bionics, Inc., et al., was filed on September 4, 2026 in the U.S. District Court for the Central District of California (Case No. 8:26-cv-02612).

Investors with losses on Beta Bionics, Inc. securities can contact the Law Offices of Howard G. Smith about the Beta Bionics, Inc. lawsuit before the November 3, 2026 lead plaintiff deadline.

Key deadlines and dates for Beta Bionics, Inc. investors

• Lead plaintiff deadline: November 3, 2026
• Class period: July 30, 2025 through February 24, 2026
• Complaint filed: September 4, 2026

What happened?

On January 8, 2026, Beta Bionics released preliminary fourth quarter 2025 financial results, revealing that new patient starts would be "up at least 36%" — lower than analysts had estimated for the quarter.

On this news, Beta Bionics' stock price fell $11.85, or 37%, to close at $20.15 per share on January 9, 2026, thereby injuring investors.

What is the Beta Bionics, Inc. lawsuit about?

The Beta Bionics, Inc. securities lawsuit alleges that, between July 30, 2025 and February 24, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Beta Bionics, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) Defendants omitted mention of the FDA Form 483 and iLet's underlying safety issues, including that the Form 483 identified over 18,000 complaints including numerous life-threatening hypoglycemic events that the Company had "failed to investigate," or even report to the FDA, with no justification; (2) the Company's statements assuring investors that its remediation efforts were advanced and the FDA's issues were "very benign," failed to accurately describe the scope and severity of the FDA's observations which made remediation much more complex and extensive than Defendants indicated to investors; (3) that the Company "could have opened a CAPA and did not" was misleading where the FDA had in fact concluded that Beta Bionics had, without justification, failed to investigate clearly serious, life-threatening customer reports; and (4) as a result, defendants' positive statements about Beta Bionics, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

"The lawsuit against Beta Bionics, Inc. alleges that, among other things, the Company failed to tell investors that Defendants omitted mention of the FDA Form 483 and iLet's underlying safety issues, including that the Form 483 identified over 18,000 complaints including numerous life-threatening hypoglycemic events that the Company had "failed to investigate," or even report to the FDA, with no justification. Beta Bionics, Inc. investors who bought during the class period may be able to pursue their losses, and the November 3, 2026 deadline is where that process begins," said Howard G. Smith of The Law Offices of Howard G. Smith.

Next steps for Beta Bionics, Inc. investors

Beta Bionics, Inc. investors who suffered losses may contact The Law Offices of Howard G. Smith to learn about pursuing their claims.

Lead plaintiff motions in the Beta Bionics, Inc. class action are due to the Court by November 3, 2026. For more information, visit the firm's website, email [email protected], or call (215) 638-4847.

If you purchased Beta Bionics, Inc. securities during the class period, you may retain counsel of your choice, or you may take no action and remain an absent class member. No class has been certified in the Beta Bionics, Inc. case so far.

Common questions from Beta Bionics, Inc. investors

Who is eligible? Investors who acquired Beta Bionics, Inc. securities from July 30, 2025 through February 24, 2026 and suffered losses may qualify for the class in the Beta Bionics, Inc. shareholder lawsuit.

What is the deadline? Lead plaintiff motions in the Beta Bionics, Inc. case are due by November 3, 2026.

Can I recover without being lead plaintiff? Yes, Beta Bionics, Inc. investors may take no action and remain absent class members.

Does it cost anything? The Law Offices of Howard G. Smith works on contingency, meaning Beta Bionics, Inc. investors owe no attorneys' fees out of pocket. Any attorneys' fees and litigation expenses are paid solely from a recovery, if achieved, and require court approval.

About The Law Offices of Howard G. Smith

The Law Offices of Howard G. Smith has helped injured investors recover their money for more than 15 years. The firm prosecutes securities fraud, takeover, and derivative litigation against public companies and their officers, directors, and advisors in federal and state courts nationwide, and has helped clients recover hundreds of millions of dollars in losses. Clients speak directly with a lawyer, who will promptly answer any question.

Prior results do not guarantee a similar outcome.

Related links

• Beta Bionics, Inc. case page, The Law Offices of Howard G. Smith
• Complaint: Holtzman v. Beta Bionics, Inc., et al., U.S. District Court for the Central District of California
• press release
• Beta Bionics, Inc. SEC filings index, EDGAR
• The Law Offices of Howard G. Smith

Contact
Howard G. Smith
The Law Offices of Howard G. Smith
3070 Bristol Pike, Suite 112
Bensalem, PA 19020
Email: [email protected] 
Telephone: (215) 638-4847
www.howardsmithlaw.com

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SOURCE Law Offices of Howard G. Smith